Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 17, Issue 7, Pages 649-659Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2017.1336086
Keywords
Opicapone; L-DOPA; Parkinson's disease; wearing-off; motor fluctuations; COMT inhibition
Categories
Funding
- BIAL - Portela Ca, S.A
Ask authors/readers for more resources
Introduction: Opicapone is a third generation, highly potent and effective catechol O-methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L-DOPA therapy.Areas covered: In this review, the authors describe the preclinical and clinical development of opicapone. In PD patients with motor fluctuations, once daily opicapone administration was well-tolerated and consistently reduced OFF-time and increased ON-time without increasing the frequency of troublesome dyskinesia, and these benefits were maintained over at least a year of continued open-label therapy.Expert commentary: With its convenient once-daily regimen, adjunct opicapone should be considered as an effective option for use in L-DOPA treated PD patients experiencing motor fluctuations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available